Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032245 | 1.00 | EPHX1 (0.37) | EPHX1EPHX2HCAR2CYP2B6 | |
| SCHEMBL20031998 | 1.00 | EPHX1 (0.37) | EPHX1EPHX2HCAR2CYP2B6 | |
| SCHEMBL5683395 | 1.00 | EPHX1 (0.37) | EPHX1EPHX2HCAR2CYP2B6 | |
| SCHEMBL17675657 | 0.98 | EPHX1 (0.38) | EPHX1EPHX2HCAR2 | |
| SCHEMBL23743045 | 0.93 | — | — | |
| SCHEMBL23697388 | 0.92 | EPHX1 (0.34) | EPHX1EPHX2HCAR2 | |
| Ammonia Solution, Strong SCHEMBL27350163 | 0.91 | EPHX1 (0.37) | EPHX1EPHX2HCAR2 | |
| SCHEMBL12984443 | 0.88 | — | — | |
| SCHEMBL14704905 | 0.81 | HCAR2 (0.38) | EPHX1EPHX2HCAR2 | |
| SCHEMBL2982280 | 0.80 | EPHX1 (0.36) | EPHX1EPHX2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245559-B2 | Nanofiltration membranes and methods of use | NOVOMER, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | GIFU UNIVERSITY (JP) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245559-B2 | Nanofiltration membranes and methods of use | MLEC, EPCAM, LNPK | EPHX1 584/4885EPHX2 723/4885HCAR2 4056/4885 |
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | APOB, TTPA, AOX1 | EPHX1 1258/4885EPHX2 1011/4885HCAR2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.